NCM·Healthcare·$100M·#372 / 520 in Healthcare
NRXP NRX Pharmaceuticals, Inc.
31HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY50
STABILITY42
VALUATION0
GOVERNANCE38
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
N/A
0
> 50% strong
Gross Margin
Revenue retained after direct costs
58.8%
83
> 50% strong
Cash Runway
Months of cash at current burn rate
7 months
13
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-4.0%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
81.3x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
N/A
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
8.3%
57
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+93.2%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE NRXP WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when NRXP's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.